Table 1.
Characteristics | ≤45 ml/min (n = 152) | 45 to 60 ml/min (n = 198) | >60 ml/min (n = 728) |
---|---|---|---|
Age in years (SD) | 75 (7) | 70 (8) | 58 (10)a |
Gender—male (%) | 75 (49) | 129 (65) | 616 (85)b |
Previous coronary artery disease (%) | 104 (68) | 116 (59) | 313 (43)b |
Previous vascular disease (%) | 54 (36) | 53 (27) | 108 (15)b |
Previous congestive heart failure (%) | 33 (22) | 15 (8) | 17 (2)b |
Hypertension (%) | 120 (79) | 113 (57) | 312 (43)b |
Smoking status active (%) | 20 (13) | 51 (26) | 265 (36)b |
Dyslipidemia (%) | 106 (70) | 128 (64) | 431 (59)b |
Diabetes (%) | 43 (28) | 41 (21) | 133 (18)b |
Chronic obstructive lung disease (%) | 26 (17) | 32 (16) | 75 (10)b |
Mean GFR in ml/min (SD) | 34 (7) | 53 (4) | 88 (23)a |
Mean body mass index in kg/m2 (SD) | 23 (4) | 25 (4) | 28 (6)a |
Median maximal CK (IQRc) | 161 (71 to 459) | 252 (97 to 964) | 356 (118 to 1143)a |
Median cardiac troponin T (IQR) | 0.19 (0.01 to 1.07) | 0.45 (0.01 to 2.31) | 0.42 (0.01 to 1.80)a |
Abnormalities on baseline ECG (%) | 87 (57) | 119 (60) | 413 (57) |
Thrombolysis criteria on baseline ECG (%) | 32 (21) | 63 (32) | 235 (32)b |
Diagnosis of MI (%) | 69 (45) | 117 (59) | 449 (62)b |
Heart failure during hospitalization (%) | 34 (22) | 30 (15) | 47 (6)b |
Use of antiplatelet agents before admission (%) | 95 (63) | 111 (56) | 298 (41)b |
Use of warfarin before admission (%) | 16 (10) | 12 (6) | 19 (3)b |
Use of β-blockers before admission (%) | 69 (45) | 78 (39) | 219 (30)b |
Use of lipid-lowering agents before admission (%) | 82 (54) | 99 (50) | 304 (42)b |
Use of ACE inhibitors/ARBs before admission (%) | 66 (43) | 65 (33) | 183 (25)b |
≤0.05 by Kruskall–Wallis test for a difference between the three groups.
P ≤ 0.05 by χ2 for a difference between the three groups.
IQR, interquartile range.